AN2 Therapeutics Q1 GAAP EPS $(0.35) Misses $(0.26) Estimate

AN2 Therapeutics (NASDAQ: ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from the same period last year.